{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
  "id": "02975667",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
  "summary": "- **Annual revenue milestone**: Achieved $208M in sales (first time >$200M), with Australasia contributing $181M.  \n- **North American expansion**: Launched Maxigesic IV/tablet (Combogesic) in US and Canada (addressable market >US$8B); restructured US distribution.  \n- **Product pipeline**: 8 patented products in R&D, 24 off-patent injectables, and 5 advanced programs (e.g., Crystaderm, capsaicin cream).  \n- **Financials**: Net debt reduced to $14.5M (from $16.2M); dividend increased to 1.8 cps (from 1.6 cps).  \n- **FY27 target**: Ambitious $300M revenue goal.  \n\n*No material trading/capital markets actions identified (e.g., no capital raising or halt).*",
  "usage": {
    "prompt_tokens": 1984,
    "completion_tokens": 190,
    "total_tokens": 2174,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:54:02.556147"
}